Josh Riggs - 02 Dec 2022 Form 3 Insider Report for Oncocyte Corp (OCX)

Role
Interim CEO
Signature
/s/ Josh Riggs
Issuer symbol
OCX
Transactions as of
02 Dec 2022
Net transactions value
$0
Form type
3
Filing time
09 Dec 2022, 19:19:41 UTC
Next filing
19 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
holding OCX Common Stock, no par value 2,308 02 Dec 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding OCX Option to Purchase Common Stock 02 Dec 2022 Common Stock 125,000 $1.33 Direct F2
holding OCX Option to Purchase Common Stock 02 Dec 2022 Common Stock 50,012 $5.34 Direct F2
holding OCX Option to Purchase Common Stock 02 Dec 2022 Common Stock 30,000 $1.39 Direct F2
holding OCX Option to Purchase Common Stock 02 Dec 2022 Common Stock 10,000 $1.17 Direct F2
holding OCX Option to Purchase Common Stock 02 Dec 2022 Common Stock 250,000 $0.4644 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Restricted Stock Units vested on May 22, 2021.
F2 25% of the options will become exercisable after one year of Reporting Person's continuous employment with Issuer from the effective date of grant, and the balance will become exercisable in 36 equal monthly installments commencing one year after the date of grant subject to Reporting Person's continued employment with Issuer on the applicable vesting dates.
F3 100% of the options will become exercisable after one year of Reporting Person's continuous employment with Issuer from the effective date of grant.